Drossman DA, Hasler WL. Rome IV: functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–61.

Article  PubMed  Google Scholar 

Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries. Am J Gastroenterol. 2018;113(1):86–96.

Article  PubMed  Google Scholar 

Holtmann G, Shah A, Morrison M. Pathophysiology of functional gastrointestinal disorders: a holistic overview. Dig Dis. 2018;35(Suppl. 1):5–13.

Article  Google Scholar 

Ohlsson B. Extraintestinal manifestations in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2022;15:17562848221114558.

Article  PubMed  PubMed Central  Google Scholar 

Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97(9):2290–9.

Article  PubMed  Google Scholar 

Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–87.

Article  PubMed  Google Scholar 

Thompson W, Heaton K, Smyth G, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46(1):78–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vu J, Kushnir V, Cassell B, Gyawali C, Sayuk G. The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders. Neurogastroenterol Motil. 2014;26(9):1323–32.

Article  CAS  PubMed  Google Scholar 

Tornkvist NT, Simrén M, Hreinsson JP, et al. Prevalence and impact of disorders of gut–brain interaction in Sweden. Neurogastroenterol Motil. 2023;35: e14578.

Article  PubMed  Google Scholar 

Fairlie T, Shah A, Talley NJ, et al. Overlap of disorders of gut-brain interaction: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(7):646–59.

Article  CAS  PubMed  Google Scholar 

Sperber AD. Epidemiology and burden of irritable bowel syndrome: an international perspective. Gastroenterol Clin. 2021;50(3):489–503.

Article  Google Scholar 

Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011;5(3):253.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talley NJ, Holtmann G, Walker MM. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol. 2015;50:601–13.

Article  CAS  PubMed  Google Scholar 

Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986–3000.

CAS  PubMed  Google Scholar 

Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manage Care Pharm. 2013;19(9):755–64.

Google Scholar 

Bosman MH, Weerts ZZR, Snijkers JT, et al. The socioeconomic impact of irritable bowel syndrome: an analysis of direct and indirect health care costs. Clin Gastroenterol Hepatol. 2023;21(10):2660–9.

Article  PubMed  Google Scholar 

Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gasteroenterol Hepatol. 2020;17(8):473–86.

Article  Google Scholar 

Rangan V, Ballou S, Shin A, et al. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey. Gastroenterology. 2020;158(3):786–8.

Article  PubMed  Google Scholar 

LeBrett WG, Chang L. Prescription pain medications for disorders of gut–brain interaction: comparing usage patterns with clinical practice recommendations. Neurogastroenterol Motil. 2023;35(8): e14645.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

Mandrik OL, Severens JH, Bardach A, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report. Value Health. 2021;24(4):463–72.

Article  PubMed  Google Scholar 

Microsoft Excel for Microsoft 365. Version 2402. Redmond (WA): Microsoft Corporation; 2024.

Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601–9.

Article  PubMed  PubMed Central  Google Scholar 

Kim DD, Do LA, Synnott PG, et al. Developing criteria for health economic quality evaluation tool. Value Health. 2023;26(8):1225–34.

Article  PubMed  Google Scholar 

Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence Policy. 2010;6(1):51–9.

Article  Google Scholar 

McCrone P, Everitt H, Landau S, et al. Cost effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome: the ACTIB randomised trial. BMC Gastroenterol. 2021;21:1–13.

Article  Google Scholar 

Everitt H, Landau S, Little P, et al. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT. Health Technol Assess. 2019;23(17):1.

Article  PubMed  PubMed Central  Google Scholar 

Dunlap LJ, Jaccard J, Lackner JM. Minimal-contact versus standard cognitive behavioral therapy for irritable bowel syndrome: cost-effectiveness results of a multisite trial. Ann Behav Med. 2021;55(10):981–93.

Article  PubMed  PubMed Central  Google Scholar 

Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Pharmacologic, dietary, and psychological treatments for irritable bowel syndrome with constipation: cost utility analysis. MDM Policy Pract. 2021;6(1):2381468320978417.

Article  PubMed  PubMed Central  Google Scholar 

Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol. 2022;20(1):136-44.e31.

Article  CAS  PubMed  Google Scholar 

McCrone P, Knapp M, Kennedy T, et al. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2008;20(4):255–63.

Article  PubMed  Google Scholar 

Stamuli E, Bloor K, MacPherson H, et al. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care. BMC Gastroenterol. 2012;12:1–9.

Article  Google Scholar 

Andersson E, Ljótsson B, Smit F, et al. Cost-effectiveness of internet-based cognitive behavior therapy for irritable bowel syndrome: results from a randomized controlled trial. BMC Public Health. 2011;11:1–7.

Article  Google Scholar 

Lalouni M, Ljótsson B, Bonnert M, et al. Clinical and cost effectiveness of online cognitive behavioral therapy in children with functional abdominal pain disorders. Clin Gastroenterol Hepatol. 2019;17(11):2236–44.

Article  PubMed  Google Scholar 

Ljótsson B, Andersson G, Andersson E, et al. Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterol. 2011;11:1–13.

Article  Google Scholar 

Philipson A, Duberg A, Hagberg L, et al. The cost-effectiveness of a dance and yoga intervention for girls with functional abdominal pain disorders. Pharmacoeconomics Open. 2023;7(2):321–35.

Article  PubMed  PubMed Central